- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
FEI Company will release its financial results for the second quarter of 2007 after the financial markets close on Tuesday, July 31, 2007. The second quarter ended on July 1, 2007.
A conference call and simultaneous webcast to discuss the results will be held on Tuesday, July 31 at 2:00 p.m. PDT (5:00 p.m. EDT). Access to the call will be available at 1-800-257-3401 (U.S., toll-free) or 1-303-262-2006 (international), with the conference title: FEI Q2 Earnings Call. A telephone replay of the call will be available at 1-800-405-2236 (U.S.) or 1-303-590-3000 (international) with the passcode: 11093645#. Both a live and recorded audio webcast of the call will be available at the investor relations section of the company's web site at http://www.fei.com/ .
About FEI Company
FEI Company is a global leader in providing innovative instruments for nanoscale imaging, analysis and prototyping. FEI focuses on delivering solutions that provide groundbreaking results and accelerate research, development and manufacturing cycles for its customers in Semiconductor and Data Storage, Academic and Industrial R&D, and Life Sciences markets. With R&D centers in North America and Europe, and sales and service operations in more than 50 countries around the world, FEI's Tools for Nanotech(TM) are bringing the nanoscale within the grasp of leading researchers and manufacturers.
For more information, please click here
Treasurer and Investor Relations Director
Copyright © FEI CompanyIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
8th Int'l Iran Nano 2015 Festival Kicks Off Work October 7th, 2015
Latest Hygienic Products Presented in Iran Nano 2015 October 7th, 2015
Discovery about new battery overturns decades of false assumptions October 7th, 2015
Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015